View Older Stories View More Recent Stories
-
Eli Lilly (LLY) PT Raised to $1,234 at Leerink Partners
-
Goldman Sachs: 'top themes we're tracking for 2026'
-
Abivax soars on report of Eli Lilly meeting French officials over possible deal
-
Here's the list of top biotech stocks to own for 2026
-
Trump to announce prescription drug price agreements
-
Bernstein on Eli Lilly (LLY): Orforglipron De-Risks the Oral GLP-1 Path
-
RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
-
Leerink on Eli Lilly (LLY): 'Orforglipron Delivers Weight Maintenance Following Injectables'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Goldman Sachs Reiterates Buy Rating on Eli Lilly (LLY)
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
Daiwa Securities Upgrades Eli Lilly (LLY) to Buy (1)
-
Lilly reports updated breast cancer drug data at medical conference
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY) Following Topline Results
-
BMO Capital on Eli Lilly (LLY): 'A True TRIUMPH'
-
FDA reportedly pressing for reviewers to speed up evaluation of Eli Lilly's weight-loss pill
-
Eli Lilly stock climbs after retatrutide delivers massive weight loss in trial
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly plans $6 billion Alabama manufacturing facility
-
Lilly completes Adverum acquisition for $3.56 per share plus CVRs
-
Lilly's Jaypirca reduces cancer progression risk by 80% in study
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.7% Yield
-
Nobel laureate Carolyn Bertozzi rejoins Eli Lilly board
-
Eli Lilly (LLY) PT Raised to $1,200 at BMO Capital
-
Eli Lilly (LLY) PT Raised to $1,163 at Guggenheim
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $950 at Berenberg
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Raised to $1,286 at BofA Securities, 'Remains in the GLP1 driver's seat'
-
Eli Lilly reduces Zepbound prices on direct platform
-
Eli Lilly's (LLY) Zepbound Reached All-Time High on TRx and NRx- Cantor Fitzgerald
-
What comes next for Eli Lilly (LLY) stock after $1T valuation?
-
Bernstein on IRA pricing: $245 really is the floor
-
Lilly to present breast cancer drug trial results at December symposium
-
Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
-
Eli Lilly (LLY) PT Raised at Bernstein on 'An Incredibly Rich Catalyst Path Ahead'
-
Eli Lilly (LLY) PT Raised to $1,290 at Morgan Stanley
-
Lilly elects Stanford chemistry professor to board of directors
-
Eli Lilly joins $1 trillion club as weight-loss drugs fuel growth
-
Eli Lilly & Co. (LLY) passes $1 trillion in market cap
-
KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
-
Breakthrough Properties partners with Eli Lilly for Philadelphia lab space
-
Lilly to open Gateway Labs site in Philadelphia
-
Eli Lilly (LLY) PT Raised to $1,182 at Truist Securities
-
Eli Lilly (LLY) PT Raised to $1,150 at JPMorgan on Growth Potential in 2026+
-
Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
-
MeiraGTx Holdings plc (MGTX) PT Raised at RBC Capital Amid LLY Deal
-
Mangoceuticals clarifies GLP-1 weight-management program launch
-
Lilly and Novo Nordisk say no affiliation with Mangoceuticals (MGRX)
